Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-28
2011-06-28
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S317000, C424S149100, C514S021100
Reexamination Certificate
active
07968518
ABSTRACT:
Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g., of formula (I, Ia or II) as defined herein, having useful properties in the prevention of Hepatitis C infections.
REFERENCES:
patent: 5994299 (1999-11-01), Carry et al.
patent: 6524570 (2003-02-01), Glue et al.
patent: 6927208 (2005-08-01), Wenger et al.
patent: 2002/0013272 (2002-01-01), Cavanak et al.
patent: 2002/0102279 (2002-08-01), Chiba et al.
patent: 2003/0213603 (2003-11-01), Ambuhl et al.
patent: 0 484 281 (1992-05-01), None
patent: 1 633 287 (2009-07-01), None
patent: 99/62540 (1999-12-01), None
patent: 02/32447 (2002-04-01), None
patent: 2004/002422 (2004-01-01), None
patent: 2005/021028 (2005-03-01), None
patent: 2006/038088 (2006-04-01), None
patent: 2006/071619 (2006-07-01), None
Inoue, et al., 2003, J. Gastroenterology, 38, 567-572.
Watashi, et al., 2003, Hepatology, 38, 1282-1288.
[Retrieved from]: http://www3.niaid.nih.gov/topics/hepatitis/hepatitisC/prevention.html, 2009, 2 pages [Retrieved on Jun. 27, 2009].
Hansson, 2004, Journal of Bioenergetics and Biomembranes, 36, 407-413.
Inoue, 2003, J Gastroenterol, 38, 567-572.
Papageorgiou, 1996, Bioorganic and Medicinal Chemistry Letters, 6, 23-26.
Steinkasserer, 1995, Journal of Virology, 69, 814-824.
Inoue, 2001, Nippon Rinsho (translation enclosed) (referred further as ‘Inoue (Nippon)’), in view of Bouchard, 2003, Journal of Virology, 77, 7713-7719 in view of Bartz, 1995, PNAS, 92, 5381-5385.
Bouchard, 2003, Journal of Virology, 77, 7713-7719.
Bartz, 1995, PNAS, 92, 5381-5385.
Inoue, 2001, Nippon Rinsho copy of translation enclosed furnished earlier.
Kakuma, J. of Gastroenterology and Hepatology, 1997, 12, 62-66.
Inoue et al. “Hepatitis C. virus and cyclosporin A”, Igaku no Ayumi, 193(12), pp. 951-954 (2000) Included are copies of the English abstract, the original doucment in Japanese, and an English translation of the original Japanese document.
Inoue et al. “Antiviral effect of cyclosporin A”, Antiviral Development and Therapy Poster Presentation, National Institutes of Health, Jun. 6-9, 1999.
Yoshiba et al. “Interferon and cyclosporin A in the treatment of fulminant viral hepatitis”, Journal of Gastroenterology, 30:67-73 (1995).
Steinkasserer et al. “Mode of action of SDZ NIUM 811, a nonimmunosupressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication”, Journal of Virology, vol. 69, 814-824 (Feb. 1995).
Watashi, et al. “Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes”, Hepatology vol. 38, No. 5 1282-1288 (2003).
Billich A et al. “Mode of Action of SDZ NIM 811, a Nonimmunosuppressive Cyclosporin A analog with Activity against Human Immunodeficiency Virus (HIV) Type 1: Interference with HIV Protein-Cyclophilin A Interactions”, Journal of Virology, vol. 69, No. 4, pp. 2451-2461 (1995).
Watashi, K. et al., “Cyclosporin A supresses Replication of Hepatitis C Virus Genome . . . ”, Williams and Wilkins, Baltimore, MD, US, 2003, Hepatology, vol. 38, No. 5, pp. 1282-1288.
Retrieved from: http://www3.niad.nih.gov/topics/hepatitisC/prevention.html, 2009, 2 pages [Retrieved on Jun. 27, 2009].
International Search Report, Mar. 6, 2006.
Renken, J., Observations under Article 115 EPC,Hoffmann Eitle, Jun. 22, 2007, pp. 2-7.
U.S. Appl. No. 11/572,110, filed Jan. 11, 2008, Cornu-Artis, C., et al.
U.S. Appl. No. 11/720,105, filed May 24, 2007, Kai Lin , W. et al.
U.S. Appl. No. 11/719,684, filed Jan. 29, 2009, Weidmann ,B.
U.S. Appl. No. 12/444,941, filed Apr. 9, 2009, Kohjima M. et al.
EPO, Third Party Observations Under Article 115 EPC, EP 04 764 762.3 (WO 2005/021028) Novartis, Feb. 19, 2007, pp. 1-4.
EPO, Observations by third party pursuant to Art. 115 EPC, Art. 54 EPC, ART 123(2) EPC, Art. 83 EPC, Art 84 EP, Feb. 8, 2007, pp. 1-6.
Evers et al., “Synthesis of Non-immunosuppressive Cyclophilin-Binding . . . ”, Bioorganic & Medicinal Chemistry Letters, 2003, vol. 13, pp. 4415-4419.
Fukushima et al., “Fasudil hydrochloride hydrate, a rhokinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells”, 2005,Liver International, vol. 25, pp. 829-838.
Fukushima et al., “Hydroxyfasudil, a Rho-kinase (ROCK) inhibitor suppresses cell growth and collagen production in rat hepatic stellate cells”, 2003, Hepatology, vol. 38, No. 4, Suppl. 1, p. 562A.
Nakamuta et al. , “Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells”, 2005, Transplantation Proceedings, vol. 37, No. 10.
Kozlowski et al., ,Development of pegylated interferons for the treatment of chronic hepatitis C, BioDrugs, vol. 15, No. 7, pp. 419-429 (2001).
Inoue et al., “Combined interferon A2b and cyclosporine A in the treatment of chronic hepatitis C: controlled trial”, Journal of Gastroenterol, vol. 38, No. 6, pp. 567-572, , Jun. 2003.
Agid et al., “MR diffusion-weighted imaging in a case of West Nile virus encephalitis”, Dec. 23, 2003, Neurology, vol. 61., No. 12, pp. 1821-1823.
Ravindra, K. V. et al., “West Nile virus-associated encephalitis in recipients of renal and pancreas transplants . . . ”, May 1, 2004, Clinical Infectious Diseases, vol. 38, No. 9, pp. 1257-1260.
Quesniaux, V. F. J. et al., “Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive . . . ”, 1987, European Journal of Immunology, vol. 17, No. 9, pp. 1359-1365.
Papatheodoridis and Cholongitas (2003), J. Viral Hep., 11:287-296.
Watashi, Koichi et al. “Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents”, Biosis, Biosciences Information Service , Philadelphia, PA, US; vol. 55, No. 1, pp. 105-110, Jun. 2005.
Duncan and Youossi (2003), Cleveland Clinic, J. Med., 70:S21-S26.
Tripi et al., “Interferon-alpha Alone versus interferon-alpha plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Pervious Interferon-alpha treatment.”, BioDrugs, vol. 13, No. 4, pp. 229-304 (Apr. 2000) (Abstract).
Brown et. al., “Liver Transportation”, Current opinion gastroenterology, vol. 17, No. 3, pp. 299-303 (May 2001).
Ferenci, P., International Journal Of Clinical Practice, vol. 57, No. 7, pp. 610-615, “Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C”, Sep. 7, 2003.
Manns, M.P., et al., The Lancet, vol. 358, No. 9286, pp. 958-965, “Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial”, Aug. 2001.
Manzarbeitia, C., et al., “40 kDa Peginterferon alfa-2A (PEGASYSs®) as a prophylaxis agent hepatitis C infection recurrence after liver transplantation (LT): preliminary results of a randomized multicenter trial”, p. 406A, AbstractsAASLD No. 938, Oct. 2001.
Nakagawa, M., et al., Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, FL, vol. 313, No. 1, pp. 42-47, “Specific inhibition of hepatitis C virus replication by cyclosporin A”, Jan. 2, 2004.
Bizollon T. et al., “Histological Benefit of Retreatment by Pegylated Interferon Alfa-2b and Ribavirin in Patients with Recurrent Hepatits C Virus Infection Posttransplantation”, American Journal of Transplantation, vol. 7, pp. 448-453, (2007).
Cotler, Scott J. et al., “A Pilot Study of the Combination of Cyclosporin A and Interferon Alfacon-1 for the Treatment of Hepatitis C in Previous Nonresponder Patients”, J Clin Gastroenterol , vol. 36 (4), pp. 352-355, (2003).
Shiffman (2004) Cleveland Clinic J. Med. 71:S13-S16.
Dasilva et al. (2002) J. Gastroenterol 37:732-36F.
Heathcote et al. (1998) Hepatology 27:4, pp. 1136-1143.
Package Insert for Intron A, Revision Jul. 2007.
Hijikata Makoto
Shimotohno Kunitada
Watashi Koichi
Bautista Regina
Fischer Leslie
Gudibande Satyanarayana R
Kosar Andrew D
Novartis AG
LandOfFree
Use of modified cyclosporins for the treatment of HCV disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of modified cyclosporins for the treatment of HCV disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of modified cyclosporins for the treatment of HCV disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2698062